Mouthwashes: allies or enemies of good taste
A 12-week trial exploring semaglutide versus liraglutide in managing glycemic control in patients with type 2 diabetes yielded the following results [11]: Semaglutide demonstrated dose-dependent reductions in HbA1c levels and body weight, with up to 81% of patients achieving an HbA1c level below 7%
Western European nations like Germany, the UK, France, and the Netherlands are actively integrating weight control as a component of chronic disease prevention
Two years ago, walking the halls of CPHI, I saw booth after booth of semaglutide API suppliers, pen manufacturers, and finished formulation players
However, there are no completed large-scale human clinical trials
When an Integrative Approach Makes Sense There are situations where GLP-1 medications are medically necessary, particularly in advanced type 2 diabetes or severe metabolic disease